Enliven Therapeutics (ELVN) vs Organon (OGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Enliven Therapeutics (ELVN) has outperformed Organon (OGN) over the past year, gaining 113.9% versus a gain of 92.9%. Over five years, ELVN leads with a +254.6% price change compared with -55.4% for OGN. Organon is the larger company by market cap ($3.65 billion vs $3.42 billion), about 1.1 times the size.
Organon pays a dividend yielding 0.58%, while Enliven Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELVN | OGN |
|---|---|---|
| Share price | $46.53 | $13.89 |
| Market cap | $3.42B | $3.65B |
| 1-day change | +0.26% | -0.14% |
| YTD return | +202.14% | +93.72% |
| 1-year return | +113.93% | +92.92% |
| 5-year return | +254.65% | -55.38% |
| P/E ratio (TTM) | — | 17.81 |
| Forward P/E | — | 3.81 |
| EPS (TTM) | $-1.69 | $0.78 |
| Dividend yield | 0.00% | 0.58% |
| Annual dividend | $0.00 | $0.08 |
| Revenue (latest FY) | — | $6.22B |
| Revenue growth (YoY) | — | -2.92% |
| Net income (latest FY) | $-103.69M | $187.00M |
| Gross margin | — | 53.30% |
| Net margin | — | 3.01% |
| 52-week high | $62.32 | $13.94 |
| 52-week low | $14.79 | $5.69 |
| Distance from 52-week high | -25.34% | -0.36% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +59.75% | -25.63% |
| Average volume | 1.36M | 2.74M |
| Shares outstanding | 73.60M | 262.62M |
| Employees | 65 | 10,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELVN has outperformed OGN by 21.0 percentage points over the past year.
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
ELVN vs OGN FAQ
Which is bigger, Enliven Therapeutics or Organon?
Organon (OGN) is larger, with a market capitalization of $3.65B compared with $3.42B for Enliven Therapeutics (ELVN).
Which stock has performed better over the past year, ELVN or OGN?
ELVN returned +113.93% over the past 12 months, compared with +92.92% for OGN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Enliven Therapeutics or Organon?
Organon pays a dividend yielding 0.58%, while Enliven Therapeutics does not currently pay a regular dividend.
Are Enliven Therapeutics and Organon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.